Please login to the form below

Not currently logged in

Elan names new chairman

Elan Corporation has named former GSK vice chairman pharmaceuticals, Robert A Ingram, as chairman effective January 2011

Neuroscience-focused biotechnology company, Elan Corporation, has named former GlaxoSmithKline (GSK) vice chairman pharmaceuticals, Robert A Ingram, as chairman effective January 26, 2011.

Ingram, who was also formerly CEO of Glaxo Wellcome, will succeed Kyran McLaughlin, who announced his intention to step down as non-executive chairman for Ireland-based Elan in April 2010.

Speaking on the announcement, McLaughlin said: "With top level leadership experience at Glaxo Wellcome and GlaxoSmithKline, Bob has a proven track record of successful leadership and a deep understanding of the industry overall. I am proud to be turning over the chairmanship to such a capable and high integrity leader and know that he will make many contributions as the company continues to develop and advance."

Ingram currently serves on several boards of directors already, including Allergan, Edwards Lifesciences Corporation and Valeant Pharmaceuticals. He has also acted as an advisor to GSK CEO, Andrew Witty, since January 2010.

Commenting on his appointment, Ingram said: "I am impressed with the progress [Elan] has made over the past several years in advancing the science, improving its financial performance, and constructing unique and far reaching collaborations which will enable the company to continue to invest in science and innovate within the world of novel therapeutic advances.

"I look forward to working with the board and the management team to deliver long term benefits to science, patients and shareholders."

7th December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...